Induction of T helper cell type 1 response and elimination of HBeAg during treatment with IL-12 in a patient with therapy-refractory chronic hepatitis B

This study reports the increase of immunoregulatory T helper cell type 1 response and elimination of HBV-DNA during IL-12 therapy in a patient with chronic hepatitis B virus infection who had not responded to three previous interferon-alpha therapies and one treatment with Famciclovir over a period...

Full description

Saved in:
Bibliographic Details
Published inHepato-gastroenterology Vol. 48; no. 38; p. 553
Main Authors Barth, H, Klein, R, Berg, P A, Wiedenmann, B, Hopf, U, Berg, T
Format Journal Article
LanguageEnglish
Published Greece 01.03.2001
Subjects
Adjuvants, Immunologic - therapeutic use
Adult
Alanine Transaminase - blood
DNA, Viral - analysis
Hepatitis B e Antigens - blood
Hepatitis B, Chronic - immunology
Hepatitis B, Chronic - therapy
Humans
Interferon-alpha - therapeutic use
Interleukin-12 - therapeutic use
Male
T-Lymphocytes - immunology
Treatment Failure
Online AccessGet more information

Cover

More Information
Summary:This study reports the increase of immunoregulatory T helper cell type 1 response and elimination of HBV-DNA during IL-12 therapy in a patient with chronic hepatitis B virus infection who had not responded to three previous interferon-alpha therapies and one treatment with Famciclovir over a period of 6 years. The patient received IL-12 at a dose of 0.5 microgram/kg bodyweight weekly. Peripheral blood mononuclear cells were isolated before and during IL-12 application and incubated for 7 days with specific type 1 (purified protein derivative) and type 2 (tetanus-toxoid) TH cell antigens as well as with a macrophage/monocyte activating antigen (Bacille Calmette-Guérin). In the supernatants cytokines were determined by a double-sandwich ELISA. After 8 weeks HBV-DNA became negative and HBeAg seroconversion to anti-HBeAg occurred. Immunologically the loss of viremia was accompanied by a strong increase of the purified protein derivative-induced production of the type 1 cytokine interferon-gamma (1219 pg/mL before, 13,138 pg/mL after IL-12 therapy). Furthermore, Bacille Calmette-Guérin-induced secretion of the macrophage/monocyte-associated cytokines IL-1, tumor necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor was higher at the end of therapy. This case indicates that IL-12 enhances type 1 T helper cell activity which may be a predisposition for elimination of HBeAg and successful treatment of hepatitis B.
ISSN:0172-6390